Evidence Paper Review

 Quick Explanation Copied

This 2014 Expert Opinion on Therapeutic Patents review systematically categorizes proteasome inhibitor patents (2010–2013) into boron, epoxyketone, salinosporamide, metal-complex, polyphenol, and novel-competitive classes, concluding that nearly all rely on covalent warhead–peptide designs and that none achieves an optimal potency–toxicity–bioavailability balance Metcalf et al. patent review.

 Long Explanation

Scope and Structure

The authors (Metcalf, Scott, Daniel, Dou — Wayne State/Karmanos, Moffitt) searched Delphion for proteasome-inhibitor patents filed January 2010–September 2013, organizing compounds by chemical class: boronates, epoxyketones, salinosporamides, metal complexes, EGCG/polyphenols, and unique competitive designs Patent classification overview. The review correctly identifies that most patentees copy the two FDA-approved warheads (bortezomib boronate; carfilzomib epoxyketone) rather than inventing new mechanisms — a critical, honest assessment rare in patent reviews.

Note: values are biochemical IC50s from patent applications, not clinically validated potencies; several (e.g., 6f) carry ± wide uncertainty and were never advanced to trials.

Strengths and Honest Critique

The expert opinion section is the paper's best contribution: it flags that covalent warheads react off-target independently of binding Off-target warhead critique — a mechanism later confirmed by independent work Annual Review PI pharmacology. Blind spot: reliance on patent data inflates apparent novelty; patents emphasize claim scope over reproducibility, and failed/abandoned compounds are invisible Patent-bias limitation. Coverage ends 2013, omitting ixazomib/oprozomib approvals and immunoproteasome-selective agents.

Clinical Trajectory Check

The review's optimism on marizomib aged partially well — it has since entered GBM trials (NCT02330562, completed) — and combination patents (e.g., T-L inhibitor NC-022 synergizing with bortezomib) foreshadowed today's standard poly-PI regimens (NCT03155100). Its skepticism toward solid-tumor efficacy has largely held.

 BGPT Paper Review

Study Novelty

A competent snapshot of patent chemistry circa 2013; classifies known scaffolds well but introduces few new mechanisms itself.

Scientific Quality

Well-organized, transparent search strategy, honest expert opinion; limited by patent-literature source bias and cutoff at late 2013.

Study Generality

Useful to medicinal chemists and oncology drug developers broadly, though focused on one target class.

Study Usefulness

Practical map of the competitive patent landscape; the mechanistic critique of warheads remains cited and prescient.

Study Reproducibility

Search dates and database stated, but individual patent claim data cannot be independently re-verified from the summary text alone.

Explanatory Depth

Good mechanistic grounding (Thr1 chemistry, active-site selectivity) but no quantitative SAR or structural modeling.